Acrocephalosyndactylia
|
0.880 |
Biomarker
|
disease |
MGD |
A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes.
|
11274405 |
2001 |
Acrocephalosyndactylia
|
0.880 |
GermlineCausalMutation
|
disease |
ORPHANET |
Novel molecular pathways elicited by mutant FGFR2 may account for brain abnormalities in Apert syndrome.
|
23593218 |
2013 |
Acrocephalosyndactylia
|
0.880 |
Biomarker
|
disease |
CTD_human |
Apert syndrome: report of a case with emphasis on craniofacial and genetic features.
|
19186770 |
2009 |
Acrocephalosyndactylia
|
0.880 |
Biomarker
|
disease |
CTD_human |
Genotype-phenotype correlation for nucleotide substitutions in the IgII-IgIII linker of FGFR2.
|
9002682 |
1997 |
Acrocephalosyndactylia
|
0.880 |
GermlineCausalMutation
|
disease |
ORPHANET |
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities.
|
15282208 |
2004 |
Acrocephalosyndactylia
|
0.880 |
GeneticVariation
|
disease |
LHGDN |
Apert syndrome with preaxial polydactyly showing the typical mutation Ser252Trp in the FGFR2 gene.
|
16440883 |
2005 |
Acrocephalosyndactylia
|
0.880 |
GeneticVariation
|
disease |
LHGDN |
Differential effects of FGFR2 mutation in ophthalmic findings in Apert syndrome.
|
17251833 |
2007 |
Acrocephalosyndactylia
|
0.880 |
Biomarker
|
disease |
MGD |
Brain phenotypes in two FGFR2 mouse models for Apert syndrome.
|
20077479 |
2010 |
Acrocephalosyndactylia
|
0.880 |
Biomarker
|
disease |
LHGDN |
A role for fibroblast growth factor receptor-2 in the altered osteoblast phenotype induced by Twist haploinsufficiency in the Saethre-Chotzen syndrome.
|
15829502 |
2005 |
Acrocephalosyndactylia
|
0.880 |
Biomarker
|
disease |
LHGDN |
Understanding the molecular basis of Apert syndrome.
|
15622262 |
2005 |
Acrocephalosyndactylia
|
0.880 |
Biomarker
|
disease |
CTD_human |
RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis.
|
17694057 |
2007 |
Acrocephaly
|
0.400 |
Biomarker
|
disease |
CTD_human |
FGFR2 mutation associated with clinical manifestations consistent with Antley-Bixler syndrome.
|
9605588 |
1998 |
Acrocephaly
|
0.400 |
Biomarker
|
disease |
CTD_human |
FGFR2 mutation in clinically nonclassifiable autosomal dominant craniosynostosis with pronounced phenotypic variation.
|
8957519 |
1996 |
Acrocephaly
|
0.400 |
Biomarker
|
disease |
CTD_human |
Syndromic craniosynostosis with elbow joint contracture.
|
16465081 |
2006 |
Acrocephaly
|
0.400 |
Biomarker
|
disease |
HPO |
|
|
|
Addictive Behavior
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
FGFR2 appeared to be a pivotal molecule for the survival of UACC812/LR as they became independent of the HER2 pathway, suggesting that a switch of addiction from the HER2 to the FGFR2 pathway enabled cancer cells to become resistant to HER2-targeted therapy.
|
21377448 |
2011 |
Addictive Behavior
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
FGFR2 is highly expressed and activated in NCI-H716 cells, and FGFR selective small molecule inhibitors or FGFR2 shRNA strongly inhibited cell viability in vitro, indicating "addiction" of NCI-H716 cells to FGFR2.
|
24968263 |
2014 |
Adenocarcinoma
|
0.090 |
GeneticVariation
|
group |
BEFREE |
FGFR2 mutations occur in approximately 7% of adenocarcinomas of the endometrium.
|
21285871 |
2011 |
Adenocarcinoma
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In contrast, a recent study has revealed that the overexpression of KGFR in salivary adenocarcinoma induces growth inhibition, cell differentiation and apoptosis.
|
16391783 |
2006 |
Adenocarcinoma
|
0.090 |
Biomarker
|
group |
BEFREE |
Our results provided significant insight into the mechanism of KGFR tumor suppression and suggest that KGFR gene therapy might be a viable method of inhibiting human salivary adenocarcinoma growth.
|
11562460 |
2001 |
Adenocarcinoma
|
0.090 |
AlteredExpression
|
group |
LHGDN |
Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.
|
14559809 |
2003 |
Adenocarcinoma
|
0.090 |
AlteredExpression
|
group |
BEFREE |
We hypothesized that FGFR2 amplification is associated with FGFR2 expression, resulting in tumor growth and poorer outcome in esophagogastric junction (EGJ) adenocarcinoma.
|
26933914 |
2016 |
Adenocarcinoma
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Archived tissue from NSCLC (adenocarcinoma and SCC; n = 321) and adjacent bronchial epithelial specimens (n = 426) were analyzed for the immunohistochemical expression of bFGF, FGFR1, and FGFR2, and the findings were correlated with clinicopathologic features of the patients.
|
18829480 |
2008 |
Adenocarcinoma
|
0.090 |
Biomarker
|
group |
BEFREE |
Comprehensive genomic profiling in <i>FGFR2</i>-altered GEA parallels the heterogeneity findings in <i>HER2</i>-amplified GEA and adds support to the utility of genomic profiling in advanced gastroesophageal adenocarcinomas.
|
31249137 |
2019 |
Adenocarcinoma
|
0.090 |
Biomarker
|
group |
BEFREE |
Moreover, the K-sam gene is amplified preferentially in poorly differentiated adenocarcinoma of scirrhous carcinoma.
|
8440743 |
1993 |